Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More
Eli Lilly Issues Guidance For 2018, New Drugs To Drive Top Line
European advisory group backs Lilly's Taltz for psoriatic arthritis; shares up 1% (Seeking Alpha)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $57.00 to $60.00.

BofA Merrill Lynch noted, “LLY offers a good mix of compelling valuation, an attractive dividend yield with a track record of returning cash to shareholders, and pipeline optionality. Several promising late-stage pipeline assets are underappreciated, in our view, and could be transformative to LLYs growth trajectory (ramucirumab, solanezumab and the four Phase III diabetes assets - two basal insulins, empagliflozin and dulaglutide).”

Eli Lilly & Co. closed on Tuesday at $51.88.

Latest Ratings for LLY

DateFirmActionFromTo
Nov 2017Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2017Leerink SwannMaintainsMarket Perform
Oct 2017BarclaysMaintainsOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!